<DOC>
	<DOCNO>NCT00635466</DOCNO>
	<brief_summary>The purpose study examine technical oncological feasibility laparoscopic surgery rectal carcinoma</brief_summary>
	<brief_title>Phase II Trial Evaluate Laparoscopic Surgery Stage 0/I Rectal Carcinoma</brief_title>
	<detailed_description>Recently report randomized controlled trial demonstrate laparoscopic surgery comparable superior open surgery regard long-term outcome colon rectosigmoidal carcinoma ; however , controversy persists regard appropriateness laparoscopic surgery patient rectal carcinoma uncertainty long-term outcome , concern safety procedure . In Japan , lateral lymph node dissection combine total mesorectal excision remain standard surgical procedure patient advance low rectal carcinoma , lateral lymph node dissection laparoscopy still unexplored frontier . To examine technical oncological feasibility laparoscopic surgery rectal carcinoma , phase II trial conduct patient preoperative diagnosis stage 0/I rectal carcinoma , direction Japan Society Laparoscopic Colorectal Surgery , lead hospital laparoscopic surgery colorectal carcinoma Japan member .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<criteria>1 . Histologically proven rectal carcinoma . 2 . Tumor locate rectum . 3 . Clinical Tis , T1 , T2 N0 M0 4 . Without multiple lesion carcinoma situ 5 . Tumor size &lt; 8 cm . 6 . Sufficient organ function . 7 . No bowel obstruction . 8 . No history major colorectal surgery . 9 . No history chemotherapy radiotherapy . 10 . Provide write informed consent . 1 . Synchronous metachronous ( within 5 year ) malignancy carcinoma situ . 2 . Pregnant lactating woman . 3 . Severe mental disease . 4 . Severe pulmonary emphysema , interstitial pneumonitis ischemic heart disease . 5 . Continuous systemic steroid therapy .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>laparoscopic surgery , rectal carcinoma , phase II trial</keyword>
</DOC>